MAFALAN® (Melphalan) for Injection

About MAFALAN® (melphalan) for Injection

MAFALAN® is the company’s first self-manufactured product, indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma; and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. 

As a domestic substitute for the imported product Evomela®, MAFALAN® leverages localized manufacturing advantages to achieve a dual breakthrough of "international quality with Chinese cost," offering a more accessible treatment option for patients with multiple myeloma and those undergoing autologous hematopoietic stem cell transplantation.

LOCALIZATION CREATES TRIPLE VALUE

Supply Stability
An independent and controllable production system that mitigates international supply chain risks.

Quality Reliability
Critical quality attributes (CQAs) such as stability, pharmacokinetics, and tissue distribution are consistent with the original imported product and, in some aspects, superior to domestically produced counterparts.

Economic Accessibility
Treatment costs are significantly reduced, enhancing affordability and accessibility for transplant patients in China.